<DOC>
	<DOC>NCT00757757</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases</brief_summary>
	<brief_title>A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<criteria>Patients with asymptomatic castrateresistant prostate cancer with bone metastases who have not received any bisphosphonates in the 12 months prior to enrollment 18 years old and over Plan to be on cytotoxic or biologic therapy during study Active dental problems Active heart complications Active infection Patients with moderate to severe swelling due to fluid Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>bone metastases</keyword>
	<keyword>anti-M-CSF</keyword>
	<keyword>M-CSF antibody</keyword>
	<keyword>M-CSF</keyword>
	<keyword>Prostate Cancer with bone metastases</keyword>
</DOC>